Coronavirus Notebook: Australia OKs GSK’s Sotrovimab For COVID-19, Iran Takes SpikoGen Vaccine Into Phase III
Bavarian Nordic is testing the potential of its ABNCoV2 vaccine as a booster dose for people with previous infection or vaccination. Brazil has received requests from Pfizer/BioNTech and AstraZeneca to trial vaccines as booster doses, and has asked for more immunogenicity data on SinoVac’s CoronaVac.
You may also be interested in...
Having decided to suspend 12 million doses of Sinovac’s coronavirus vaccine, Brazil’s regulatory agency says it will need to make its own on-site assessment of conditions at the Chinese facility that makes the product.
The UK has pipped the EU to the post in granting a marketing authorization to what the health secretary describes as “a significant addition to our armoury to tackle COVID-19.”
The Coalition for Epidemic Preparedness and Innovations is working with China’s ZerunBio to develop prototype and variant vaccine candidates, and Australia believes MSD’s molnupiravir could be a potential treatment for COVID-19. The European Medicines Agency is looking into more possible side effects with two mRNA vaccines.